The device was not returned to edwards for evaluation.The device history record (dhr) was reviewed and shows that this device met all manufacturing specifications for product release prior to distribution.No issues were identified that would have impacted this event.Valve thrombosis is a rare and well-recognized complication of prosthetic valves.Valve thrombosis is the formation of significant blood clots forming on the valve.These clots could significantly impact the functionality of the valve resulting in heart failure or thromboembolism.Immediate intervention, either by thrombolytic therapy or valve replacement is required for significant thrombosis.Alternatively, there may be cases where the patient is placed on an anticoagulant to treat thrombosis.A manufacturing related issue was not identified.A definitive root cause could not be determined.Edwards lifesciences will continue to monitor all reported events.No further actions are required at this time.
|
It was reported that a 25mm bioprosthetic aortic valve, implanted for 17 years and two (2) months, was explanted due to leaflet thickening caused by thrombosis, calcification, degeneration, and stenosis.The explanted device was replaced with a 23mm valve.The patient tolerated the procedure well.On pod #2, the patient was started on coumadin for thrombus noted on aortic valve during surgery.Patient was discharged on pod #7.
|